comunicacio

IDIBELL participates in the European Project Evomet, coordinated by IRB Barcelona, which will train future leaders in metastasis research

Cancer, Molecular Mechanisms and Experimental Therapy in Oncology Program - Oncobell, Vascular biology and signalling  / By

The goal is to train 15 young researchers in the understanding of metastatic processes and their evolution, with the aim to identify therapeutic solutions. The Evomet consortium is formed by 13 institutions, which include several of the best academic, clinical and industrial centres working in cancer research and metastasis research in Europe. Awarded in the […]

IDIBELL participates in the European Project Evomet, coordinated by IRB Barcelona, which will train future leaders in metastasis research Read More »

The use of water pipes and passive exposure to their smoke are as harmful as conventional tobacco

Cancer, Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, Tobacco control research  / By

Smoking in water pipes and passive exposure to the smoke they produce, increase the risk of lung cancer and other cardiovascular diseases. It is for this reason that its use should be regulated and compliance with the regulations guaranteed.

The use of water pipes and passive exposure to their smoke are as harmful as conventional tobacco Read More »

IDIBELL scientists fins a new combination of drugs to treat rhabdomyosarcoma, a highly aggressive tumor in children

Cancer, Molecular Mechanisms and Experimental Therapy in Oncology Program - Oncobell, Tumor and stromal chemoresistance  / By

The chemoresistance group of IDIBELL and ICO’s ProCURE Program, led by Alberto Villanueva, has transferred its experience in generating orthotopic mouse models in adult patients to the pediatric field.

IDIBELL scientists fins a new combination of drugs to treat rhabdomyosarcoma, a highly aggressive tumor in children Read More »

Age and male sex, key factors in the risk of mortality after hospital admission due to COVID-19

Infections of the Respiratoy Tract and in Immunocompromised Patients , Infectious disease and transplantation Program, Translational Medicine Area / By

A study with the participation of IDIBELL adds complete information on the complications and prognosis of the first 4,035 patients with COVID-19 in the country.

Age and male sex, key factors in the risk of mortality after hospital admission due to COVID-19 Read More »

A study determines the prevalence of mutations in two polymerases in patients with hereditary cancer

Cancer, Hereditary cancer , Molecular Mechanisms and Experimental Therapy in Oncology Program - Oncobell / By

A team from the IDIBELL-ICO Hereditary Cancer group has studied more than 2,800 patients with a possible hereditary cancer to determine the frequency of pathogenic mutations in the corrective region of two polymerases.
Identifying these mutations can facilitate the early diagnosis and the personalized treatment of these patients.

A study determines the prevalence of mutations in two polymerases in patients with hereditary cancer Read More »

Anna Veiga, new IDIBELL Ombudsperson

Immunity, inflammation and cancer, Pluripotent Stemm Cell Therapy , Regenerative Medicine Area, Regenerative Medicine Program / By

The appointment coincides with the constitution of the Research Integrity Committee (CIR), chaired by the Ombudsperson and including different members of the IDIBELL research community, and the update of the “Guide to Good Practices in Research in Health Sciences”.

Anna Veiga, new IDIBELL Ombudsperson Read More »

Scroll to Top